Fig. 4: Prognosis of NGS-MRD evaluation when compared to WT1 expression in CR and NPM1 MRD. | Blood Cancer Journal

Fig. 4: Prognosis of NGS-MRD evaluation when compared to WT1 expression in CR and NPM1 MRD.

From: Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA study

Fig. 4

Panels A–C represent the cumulative incidence of relapse, relapse-free survival, and overall survival according to NGS-MRD in CR1 status in the 84 patients with low WT1 expression in CR1. Panels D–F represent the cumulative incidence of relapse, relapse-free survival, and overall survival according to NGS-MRD in CR1 and NPM1 MRD assessed by NGS in the 67 NPM1 mutated patients. p-values are for the log-rank test for RFS and OS and for the Gray test for CIR. Data were not censored at allogeneic hematopoietic stem cell transplantation.

Back to article page